The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...
Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback